Mammalian growth factor

- New York University

A truncated mammalian growth factor, displaying homology to both basic and acidic fibroblast growth factor in a single polypeptide, is disclosed herein. The growth factor is substantially smaller (i.e. has fewer amino acid residues) than the full-length mammalian growth factor, has a higher affinity for fibroblast growth factor receptors than full-length K-FGF and basic fibroblast growth factor and increased mitogenic activity. Also disclosed herein are DNA sequences encoding the truncated growth factor, pharmaceutical formulations containing the truncated growth factor and methods to heal burns and wounds in a mammal by administering the pharmaceutical formulations.

Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

1. A polypeptide having the amino acid sequence as set forth in SEQ. ID NO: 1.

2. A pharmaceutical formulation for treating a mammal suffering from wounds or burns comprising a truncated K-FGF protein having a molecular weight of about 14,000 daltons and an average FGF receptor binding affinity of about 9.5.times.10.sup.-11 M and a pharmaceutically acceptable carrier or diluent.

3. The pharmaceutical formulation of claim 2 comprising a topical pharmaceutical formulation.

4. The pharmaceutical formulation of claim 2 wherein said protein has about 4 to 5 times greater mitogenic activity than full-length K-FGF when assayed in, the BALB/c-3T3 mitogenic assay.

5. A truncated K-FGF protein having a molecular weight of 14,000 Daltons, and an average FGF receptor binding affinity of about 9.5.times.10.sup.-11 M.

6. The truncated protein of claim 5 wherein said protein has about 4 to 5 times greater mitogenic activity than full-length K-FGF when assayed in the BALB/c-3T3 mitogenic assay.

7. A pharmaceutical formulation for treating a mammal suffering from wounds or burns comprising a polypeptide having the amino acid sequence as set forth in SEQ. ID NO: 1 and a pharmaceutically acceptable carrier or diluent.

8. The pharmaceutical formulation of claim 7 comprising a topical pharmaceutical formulation.

Referenced Cited
U.S. Patent Documents
4444760 April 24, 1984 Thomas
4716102 December 29, 1987 Levy
5106731 April 21, 1992 Salhudden et al.
5126323 June 30, 1992 Rogers et al.
5352589 October 4, 1994 Bergonzoni et al.
5387673 February 7, 1995 Seddon et al.
Foreign Patent Documents
WO 8607595 December 1986 WOX
Other references
  • Moscatelli et al., Fed. Proc., 45:6, 1382, 1986. Abraham et al., Science, 233:545-548, 1986. Gimenez-Gallego et al., Biochem. Biophys. Res. Comm., 135:611-617, 1986. Sakamoto et al., Proc. Natl. Acad. Sci., 83:3997-4001, 1986. Taira et al., Proc. Natl. Acad. Sci., 84:2980-2984, 1987. Rueger et al., Antibiot. Chemother. (Basel), 32:43-7, 1984 (abstract only). Boldogh et al., Int. J. Cancer, 28:469-474, 1981 (abstract only). Abraham et al., EMBO J., 5:10, 2523-2528, 1986. Esch et al., Proc. Natl. Acad. Sci., 82:6507-6511, 1985. Delli-Bovi et al., Cell, 50:729-735, 1987. Delli-Bovi et al., Proc.Natl. Acad. Sci., 84:5660-5664, 1987. Delli-Bovi et al., Mol. and Cell. Bio., 8:2933-2941, 1988. Huebner et al., Onc. Res., 3:263-270, 1988. Quarto et al., Onc. Res., 5:101-110, 1989. Velcich et al., Onc. Res., 5:31-37, 1989. Basilico et al., Annals of N.Y. Acad. Sci., 567:95-103, 1989. Kaner et al., Science, 248:1410-1413, 1990. Mansukhani et al., Proc. Natl. Acad. Sci., 87:4222-4225, 1990. Talarico et al., Proc. Natl. Acad. Sci., 87:4222-4225, 1990. Curatola et al., Mol. and Cell. Bio., 10:2475-2484, 1990. Talarico et al., Mol. and Cell. Bio., 11:1138-1145, 1991. Mansukhani et al., Proc. Natl. Acad. Sci., 89:3305-3309, 1992. Bernstein, S.C. et al., PNAS 82: 1726-1730, 1980.5. Lo, S.C., et al., AJP 118:7-13, 1985. Diamond, A. et al., Nature 305: 112-116, Sep., 1983. Diamond, A. et al., Science 225:516-519, Aug., 1984. Garrity, R.R. et al., Gene 68:63-72. Lerman, M.I. et al., Int J. Cancer 37: 293-302, 1986. Colburn, N.H. et al., Mol. & Cell. Biol 3:1182-1186, 1983. Colburn, N.H. et al., Cancer Research 48:1195-1200, 1988. 181162w, Chem. Abs. 108, 1986. 164592z, Chem. Abs. 101, 1984. 4527g, Chem. Abs. 96, 1982. 147328h, Chem. Abs. 105, 1986. Gallego et al., Biochem & Biophys. 135:2, 541-548, 1986. Weiss et al., Clin. Res., 34:2, 537A, 1986. 165184n, Chem Abs. 105, 1986. 192304z, Chem Abs. 107, 1987. Abraham et al., Science, 223:545-548, Aug., 1986.
Patent History
Patent number: 5883071
Type: Grant
Filed: Jun 7, 1995
Date of Patent: Mar 16, 1999
Assignee: New York University (New York, NY)
Inventors: Claudio Basilico (New York, NY), Daniela Talarico (New York, NY)
Primary Examiner: Marianne P. Allen
Law Firm: Darby & Darby
Application Number: 8/478,485
Classifications
Current U.S. Class: 514/2; 514/12; Proteins, I.e., More Than 100 Amino Acid Residues (530/350); Hormones, E.g., Prolactin, Thymosin, Growth Factors, Etc. (530/399)
International Classification: C07K 14475; C07K 1450; A61K 3818;